CCM
ORMP icon

Corsair Capital Management’s Oramed Pharmaceuticals ORMP Stock Holding History

Corsair Capital Management’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-47,256
Closed -$103K – 112
2023
Q1 		$103K Buy
+47,256
New +$150K 0.04% 88

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Corsair Capital Management's ORMP Position: Q2 2023 in Review

Corsair Capital Management sold out of Oramed Pharmaceuticals (ORMP) in Q2 2023, closing a stake of 47,256 shares — an estimated $103K sold.

Corsair Capital Management first reported a position in ORMP in Q1 2023 and held it in 1 quarter. The position peaked at $103K in Q1 2023. 50 funds tracked by Wall St. Rank hold ORMP as of Q2 2023.

  • Corsair Capital Management reported no remaining Oramed Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Corsair Capital Management sold 47,256 Oramed Pharmaceuticals shares in Q2 2023, an estimated $103K.
  • Corsair Capital Management first reported a position in Oramed Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Corsair Capital Management's Oramed Pharmaceuticals position peaked at $103K in Q1 2023.
  • 50 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2023.

Based on Corsair Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.